More of the Same<br />By Rev Shark<br />RealMoney.com Contributor<br />8/28/2009 8:34 AM EDT <br /><br />A trend is a trend is a trend. <br />But the question is, will it bend? <br />Will it alter its course <br />Through some unforeseen force <br />And come to a premature end? <br />-- Alec Cairncross<br /><br />It's easy for market players to overthink the market action. That is especially the case now as we experience the most chaotic economic situations any of us have ever seen. It is almost impossible to not be influenced by the fundamental news and our personal experiences with a struggling economy. <br /><br />This market continues to reward those who don't think too much but rather simply respect the power of the uptrend. Contemplating whether the market action has been justified has not been a moneymaker. The fact that so many people are struggling to embrace the market is a big reason it keeps running. There is a constant hunt to put money to work even among the skeptics, and that keeps producing action like yesterday, when market action looked weak at first but ended up gaining steam all day. <br /><br />One reason we are seeing so many bearish comments about the market lately is that this action is almost monotonous in its consistency. Active market players tend to thrive on volatility and change, and this market is primarily a dream for the buy-and-holders who do nothing but sit and watch as things trend higher and higher. <br /><br />My advice remains the same: Respect the price action and don't try to be overly anticipatory in looking for the market to collapse. There is little in the technical action that is negative other than the fact that we have trended much higher than most folks thought possible. Sure, there are plenty of fundamental arguments against this market -- there are always fundamental arguments against the market -- but they don't matter until they do. That is why we have to stay focused on the price action and not work too hard to convince ourselves that the fundamental arguments are suddenly going to cause everyone to head for the exits. <br /><br />I'd love to offer some new and brilliant insight into the market, but the most scintillating observation I can make is that little has changed. The trend is still up, the bulls are in control and there are plenty of bearish arguments that just don't matter yet. Govern yourself accordingly. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: OVTI +15.4%, ARUN +14.3%, DLLR +11.9%, STM +7.7%, JCG +7.4% (also upgraded to Buy from Hold at Citigroup and upgraded to Hold at Needham), MRVL +7.2%, TIF +7.0%, DELL +4.2%, BNS +3.7%, CHU +3.5% (also China Unicom strikes iPhone deal - WSJ), , FRO +1.6%... Select financial names showing strength: CIT +14.1%, PMI +7.3%, MBI +7.1%, IRE +6.3%, ABK +6.1%, AIG +4.4% (Benmosche in no hurry to sell off AIG's assets - WSJ), C +4.4%, HBAN +4.1%, HIG +3.1%, FRE +3.1%, BPOP +3.1%, RF +2.9%, LYG +2.9%, GNW +2.2%, FNM +2.1%, BCS +2.1%, AIB +2.0%, FITB +1.6%, STI +1.5%, KEY +1.2%, MS +1.0%, BAC +1.0%... Select solar related names trading higher: JASO +4.2%, CSUN +3.7%, YGE +1.9%, SOL +1.4%... Select shippers ticking higher boosted by FRO results: DAC +3.4%, GNK +2.9%, DRYS +2.9%, EXM +2.6%... Select metals/mining names showing strength: AUY +2.1%, SLV +2.1%, BHP +1.7%, GOLD +1.7%, RTP +1.6%, SLW +1.3%, ABX +1.2% (initiated with Hold and $40 tgt at Jefferies), NEM +1.1% (initiated with Buy at Jefferies)... Select biotech/flu vaccine related names are ticking higher following SVA news: SVA +21.4% (wins Beijing Public Health Bureau's bid to supply seasonal Flu Vaccine Anflu to Beijing citizens), NVAX +2.7%, BCRX +1.8%, CRXL +1.3%... Other news: EURX +33.9% (announced FDA approval of its New Drug Application for ZENPEP), SCSS +21.2% (still checking), RTK +8.9% (continued momentum from yesterday's late day spike), ZQK +5.6% (still checking), NOK +4.2% (Nokia to roll out phone based on Linux software - WSJ), OMEX +3.9% (completed the first phase of Symphony project; Proceeds of any recoveries will be split with anticipated 78% of gross income retained by Odyssey), VG +2.5% (continued strength from this week's 300%+surge higher), BJ +1.1% (Cramer makes positive comments on MadMoney), HPQ +1.0% (up in sympathy with DELL)... Analyst comments: PSUN +7.7% (upgraded to Buy at Pali Research), WSM +3.2% (upgraded to Buy from Neutral at Goldman- Reuters), SNY +2.0% (upgraded to Overweight at JPMorgan), RY +1.7% (light volume; upgraded to Outperform from Neutral at Macquarie), HGSI +1.5% (UBC/IMMU will move to Phase III with 600 mg Epratuzumab; HGSI's Benlysta will hit the mkt ~ 2 yrs before Epratuzumab - Leerink Swann), BP +0.9% (initiated with an Outperform at Raymond James). <br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: NCTY -9.2%, BEBE -6.3% (light volume), MCRS -3.4% (also downgraded to Hold at Brean Murray), IMMU -2.8%, NOVL -2.3%... Other news: ALTH -16.3% (still checking), SNP -3.8% (traded lower overseas), GSI -3.5% (filed for a $60 mln mixed shelf offering), BWA -1.3% (Cramer makes negative comments on MadMoney)... Analyst comments: MOS -1.7% (downgraded to Neutral at UBS), BMY -1.2% (downgraded to Equal Weight from Overweight at Morgan Stanley), POT -1.0% (downgraded to Neutral at UBS), HTS -1.0% (downgraded to Neutral from Buy at BofA/Merrill).